Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Correction: The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.

Cell death and differentiation·2026
Same author

Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer.

ESMO real world data and digital oncology·2026
Same author

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.

ESMO open·2026
Same author

Six Years of Genetic Diagnosis of Severe Early-Onset Obesity in a French Cohort.

Obesity science & practice·2025
Same author

Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort.

ESMO open·2024
Same author

Use of perfusion device for free flap salvage after ischemia in swine.

Annales de chirurgie plastique et esthetique·2024

相关实验视频

Updated: Jul 9, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

突变TP53对晚期乳腺癌对高剂量化疗反应的影响.

P Bertheau1, F Plassa, M Espié

  • 1Service de Pathologie and INSERM ERM 0220, Hôpital Saint-Louis, 1 Ave C, Vellefaux, 75475 Paris, Cedex 10, France.

Lancet (London, England)
|September 24, 2002
PubMed
概括

乳腺癌患者的突变TP53状态与对epirubicin和cyclophosphamide化疗的完全反应有显著的相关性. 禁用TP53通路可能会提高晚期乳腺癌的治疗疗效.

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

相关实验视频

Last Updated: Jul 9, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

科学领域:

  • 在瘤学瘤学.
  • 遗传学 是一个遗传学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • TP53基因状态 (突变或野生类型) 可能会影响瘤对基因毒性化疗药物的反应,可能会影响细胞亡和细胞循环停止.
  • 关于TP53在化疗反应中的作用的临床数据是不确定的,因为瘤和治疗异质性,以及各种评估方法.

研究的目的:

  • 调查TP53基因状态与局部晚期乳腺癌患者治疗反应之间的相关性.
  • 为了确定TP53通路的失活是否会影响高度乳腺癌的化疗疗效果.

主要方法:

  • 对50例非炎症性,局部晚期乳腺癌患者的分析,这些患者接受了高剂量的epirubicin和cyclophosphamide治疗.
  • 在瘤样本中评估TP53基因状态.
  • 基于TP53突变状态的完整反应率的评估.

主要成果:

  • 在研究队列中观察到八个完整的反应.
  • 在14名患有突变TP53瘤 (p<0.0001) 的患者中,所有完整的反应都发生了.
  • 在突变TP53和完全化疗反应之间发现了显著的关联.

结论:

  • TP53通路的失活与高度,晚期乳腺癌中对epirubicin和环胺化疗的优异反应密切相关.
  • 在这种患者群体中,TP53突变状态可以作为化疗反应的预测生物标志物.